Gossamer Bio, Inc(NASDAQ:GOSS) 
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor...
Website: http://www.gossamerbio.com
Founded: 2015
Full Time Employees: 171
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 0.93
H 0.95
L 0.80
C 0.80
V 2,778,688
10EMA 0.80
20EMA 0.80
60EMA 0.80
120EMA 0.80
250EMA 0.80